|
|
| |
| |
Financial Highlights (€) |
| |
|
| |
| |
|
|
|
|
|
|
|
|
|
|
IFRS |
IFRS |
French GAAP |
| (in millions, except
percent and share amounts) |
2005 |
2004 |
2004 |
2003 |
2002 |
2001 |
2000 |
1999 |
1998 |
| |
|
|
|
|
|
|
|
|
|
| Sales |
143,168 |
121,998 |
122,700 |
104,652 |
102,540 |
105,318 |
114,557 |
75,035 |
61,810 |
| Adjusted operating income
from business segments (1) |
23,669 |
17,217 |
17,123 |
13,004 |
10,995 |
13,121 |
14,884 |
6,354 |
4,696 |
| Adjusted net operating
income from business segments |
11,902 |
8,957 |
8,792 |
6,973 |
5,868 |
7,564 |
8,035 |
– |
– |
| Cash flow from operating
activities |
14,669 |
14,662 |
14,429 |
12,487 |
11,006 |
12,303 |
13,389 |
7,012 |
7,716 |
| Adjusted
net income (Group share) (2) (3) |
12,003 |
9,131 |
9,039 |
7,344 |
6,260 |
7,518 |
7,637 |
3,349 |
2,703 |
| Adjusted
earnings per share (2) (4) |
20.33 |
15.05 |
14.68 |
11.56 |
9.40 |
10.85 |
10.80 |
4.77 |
3.86 |
| Net
dividend per share (5) |
6.48 |
5.40 |
5.40 |
4.70 |
4.10 |
3.80 |
3.30 |
2.35 |
2.00 |
| Capital
expenditures |
11,195 |
8,904 |
8,668 |
7,728 |
8,657 |
10,566 |
8,339 |
8,495 |
8,802 |
| Shareholders’
equity (as of end of period) |
40,645 |
31,608 |
31,260 |
30,406 |
32,146 |
33,932 |
32,401 |
27,669 |
25,279 |
| Net debt
(as of end of period) |
12,617 |
9,393 |
8,070 |
7,378 |
8,779 |
10,152 |
10,321 |
14,055 |
10,150 |
| Return on
equity |
35% |
33% |
31% |
26% |
20% |
24% |
27% |
13% |
11% |
| Net-debt-to-equity ratio
(as of end of period) |
32% |
31% |
27% |
26% |
29% |
31% |
33% |
50% |
39% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Financial Highlights ($) (6) |
|
|
|
|
|
|
|
|
|
|
IFRS |
IFRS |
French GAAP |
| (in millions, except
percent and share amounts) |
2005 |
2004 |
2004 |
2003 |
2002 |
2001 |
2000 |
1999 |
1998 |
| |
|
|
|
|
|
|
|
|
|
| Sales |
178,115 |
151,753 |
152,627 |
118,382 |
96,962 |
94,323 |
105,828 |
80,287 |
68,609 |
| Adjusted operating income
from business segments (1) |
29,447 |
21,416 |
21,299 |
14,710 |
10,397 |
11,751 |
13,749 |
6,799 |
5,213 |
| Adjusted net operating
income from business segments |
14,807 |
11,142 |
10,936 |
7,888 |
5,549 |
6,774 |
7,423 |
– |
– |
| Cash flow from operating
activities |
18,250 |
18,238 |
17,948 |
14,125 |
10,407 |
11,018 |
12,369 |
7,503 |
8,565 |
| Adjusted
net income (Group share) (2) (3) |
14,933 |
11,358 |
11,244 |
8,308 |
5,919 |
6,733 |
7,055 |
3,583 |
3,000 |
| Adjusted
earnings per share (2) (4) |
25.29 |
18.72 |
18.26 |
13.08 |
8.89 |
9.71 |
9.98 |
5.06 |
4.28 |
| Adjusted
earnings per ADS (2) (4) |
12.65 |
9.36 |
9.13 |
6.54 |
4.44 |
4.86 |
4.99 |
2.53 |
2.14 |
| Net dividend per ADS (6) (7) |
3.85 |
3.47 |
3.47 |
2.81 |
2.37 |
1.75 |
1.55 |
1.12 |
1.02 |
| Capital expenditures |
13,928 |
11,076 |
10,782 |
8,742 |
8,186 |
9,463 |
7,703 |
9,090 |
9,770 |
| Shareholders’ equity (as of
end of period) |
47,949 |
43,053 |
42,579 |
38,403 |
33,712 |
29,904 |
30,149 |
29,606 |
28,060 |
| Net debt (as of end of
period) |
14,884 |
12,794 |
10,992 |
9,318 |
9,207 |
8,948 |
9,604 |
15,039 |
11,267 |
| Net-debt-to-equity ratio
(as of end of period) |
32% |
31% |
27% |
26% |
29% |
31% |
33% |
50% |
39% |
|
|
|
|
|
|
|
|
|
|
|
| |
|
| |
(1)
IFRS: excluding special items and inventory valuation effect. French GAAP:
excluding special items. Click to see details of impact of special items on operating
income.
Click to see inventory valuation effect details.
(2)
IFRS: excluding special items, inventory valuation effect and TOTAL's equity
share of amortization of intangible assets related to the Sanofi-Aventis
merger. French GAAP: excluding special
items and TOTAL's
equity share of amortization of goodwill and intangible assets related to the
Sanofi-Aventis merger.
(3) IFRS: click to see
details of impact of special items on net income, Click to see inventory
valuation effect details and for details of TOTAL's equity share of amortization of
intangible assets related
to the Sanofi-Aventis
merger.
French GAAP: click to see details of impact of special items on net
income and for TOTAL's equity share of amortization of goodwill
and intangible assets related to the
Sanofi-Aventis merger.
(4) Based on
weighted-average number of fully-diluted shares (see ).
(5) 2005 dividend pending
approval at the May 12, 2006 AGM
(6) Except if
stated otherwise, dollar amounts represent euro accounts converted at the
average €/$ exchange rate for the period.
(7)
Translated solely for convenience into dollars at the Noon Buying Rates on
the respective payment dates, including for the 2005 interim dividend paid on
November 24, 2005 (3.00 €
per
share, Noon Buying Rate of the following business day i.e. November 25, 2005)
except for the 2005 final dividend (3.48 € per share) payable on May 18,
2006, which has been
translated
at the €/$ exchange rate of 1.20. In
the US, the dividend, paid to the holders of ADSs, may differ from these
figures, depending on the Noon Buying Rate used by the
Depositary
to convert euros to dollars for purposes of making payments to holders of
ADSs and depending on the tax status of the US shareholders, with respect to
the withholding
tax and the tax credit. |
|
| |
 |
|
